# US 2021/0187045 A1 · Aqueous liquid extract of spirulina for preventing or treating lipido-carbohydrate metabolism disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0187045 A1
- Document ID: US20210187045A1
- Status: Published application
- Kind: A1
- Application number: 16/771,163
- Filed: 2018-12-11
- Published: 2021-06-24
- Earliest claimed: 2017-12-12
- Assignees: Algosource
- Applicants: Algosource
- Inventors: Olivier LEPINE
- Web page: https://patentgrep.com/patent/US20210187045A1

## CPC

- A61K 35/748: Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina (algae, microalgae or microphytes A61K36/02)
- A61K 38/164: {from bacteria}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Composition comprising an aqueous liquid extract of phycobiliproteins, containing phycocyanin, which is obtained from cyanobacteria or micro-algae and which has not been subjected to any drying step, said composition being used to prevent or treat lipido-carbohydrate metabolism disorders in humans or mammals. In particular, the composition can be used to prevent or treat non-alcoholic hepatic steatosis or steatohepatitis.

## Claims

### Claim 1

A composition comprising:
an aqueous liquid extract of phycobiliproteins, containing phycocyanin, obtained from cyanobacteria or microalgae, without undergoing a drying step, used for protection of the liver against accumulation of lipids in the hepatocytes.

### Claim 2 (depends on 1)

The composition as claimed in claim 1, wherein said composition is used for preventing or treating nonalcoholic hepatic steatosis or steatohepatitis.

### Claim 3 (depends on 1)

The composition as claimed in claim 1, wherein the aqueous extract is obtained from Spirulina platensis.

### Claim 4 (depends on 1)

The composition as claimed in claim 1, wherein said composition contains only said aqueous extract, comprising a phycocyanin content of at least 0.5 g/L, preferably between 0.8 g/L and 10 g/L, more preferably between 1 g/L and 5 g/L.

### Claim 5 (depends on 1)

The composition as claimed in claim 1, wherein said composition is in liquid form and is formulated for administration by the oral route.

### Claim 6 (depends on 1)

The composition as claimed in claim 1, wherein said composition is used at preventive dosages between 0.1 and 10 mg/kg of body weight/day of phycocyanin.

### Claim 7 (depends on 1)

The composition as claimed in claim 1, wherein said composition is used at preventive dosages between 0.5 and 5 mg/kg of body weight/day of phycocyanin.
